The DOI matches its Crossref record; 93 of the 95 references it cites were found in a registry or an index.
The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease
Open accessAbstract
ABCA1, a cholesterol transporter expressed in the brain, has been shown recently to be required to maintain normal apoE levels and lipidation in the central nervous system. In addition, ABCA1 has been reported to modulate beta-amyloid (Abeta) production in vitro. These observations raise the possibility that ABCA1 may play a role in the pathogenesis of Alzheimer disease. Here we report that the deficiency of ABCA1 does not affect soluble or guanidine-extractable Abeta levels in Tg-SwDI/B or amyloid precursor protein/presenilin 1 (APP/PS1) mice, but rather is associated with a dramatic reduction in soluble apoE levels in brain. Although this reduction in apoE was expected to reduce the amyloid burden in vivo, we observed that the parenchymal and vascular amyloid load was increased in Tg-SwDI/B animals and was not diminished in APP/PS1 mice. Furthermore, we observed an increase in the proportion of apoE retained in the insoluble fraction, particularly in the APP/PS1 model. These data suggested that ABCA1-mediated effects on apoE levels and lipidation influenced amyloidogenesis in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In support of this possibility, it was recently demonstrated that ATP-binding cassette transporter A1 (ABCA1)-mediated lipidation of apoE modulates amyloid plaque formation (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al., 2005; Wahrle et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Hirsch-Reinshagen et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 overexpression or LXR/RXR agonist treatment decreased amyloid deposition [66-69].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 gene ablation in mice decreased APOE lipidation and levels and increased Aβ accumulation in APP transgenic mouse models.”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others demonstrated that modulation of ABCA1 affects Aβ levels and amyloid accumulation in vivo.”
From miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression (2012) · cites this paper as Hirsch-Reinshagen et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 deficiency leads to an increase in Aβ and amyloid deposition (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al., 2005)”
From miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression (2012) · cites this paper as Hirsch-Reinshagen et al., 2005
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, three independent studies demonstrated that ABCA1 deficiency leads to an increase in both Aβ and amyloid load in the brains of three different transgenic APP mouse models (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al., 2005).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Hirsch-Reinshagen et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of Aβ pathology, knockout of ABCA1 led to an increase in Aβ plaques (Fig. 2A) [40–42].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This transporter is of prime interest in AD because its impact on brain cholesterol metabolism modulates the brain's amyloid burden.”
From Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, deletion of ATP-binding cassette, sub-family A1 (Abca1) and liver x receptor (Lxr) genes decreased apoE levels but increased or had no effect on Aβ deposition (Hirsch-Reinshagen et al.,2005; Koldamova et al., 2005; Wahrle et al., 2005; Zelcer et al., 2007).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Hirsch-Reinshagen et al.,2005
The cited source says what the claim attributes to it.
In the citing paper
“The amyloid load in APP transgenic mice deficient in ABCA1 did not change, or even increased, when ABCA1−/− mice were crossed to various APP transgenic models [40-42].”
From Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) · cites this paper as [40]
In the citing paper
“Several studies have demonstrated that deletion of ABCA1 expression increases the amyloid burden in murine models of AD [11][12][13]”
In the citing paper
“knock-out of this gene provokes an accumulation of A peptide in the CNS [12,13,56].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
Self-citationJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Flagged first, then by citations
2 of the 95 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Lake, 1991, Lakartidningen, 88, 1271
- Miravalle, 2000, J. Biol. Chem., 275, 27110, 10.1016/S0021-9258(19)61486-9 · DOI
Cited by
Sorted by citations
Items 201–232 of 232
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
Garliyev, V., Lyssenko, C. A., Wiener, J. P., Praticò, D., & Lyssenko, N. N. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae060 · Cited by 2
Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D. S., Lamb, B. T., Montine, T. J., Schaffer, C. B., Schneider, J. A., et al. (2014) · Cited by 1
Self-citationSearcy, J. L. (2009) · UKnowledge (University of Kentucky) · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Manotas, M. R. (2009) · Gredos (University of Salamanca) · doi:10.14201/gredos.76537
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Non‐amyloid Approaches To Alzheimer's Disease
Veng, L., Savage, M. J., Barrow, J. C., & Zerbinatti, C. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc253
ABCA1, Apoe and apoA-I As Potential Therapeutic Targets for Treating Alzheimer’s Disease
Namjoshi, D., Stukas, S. K., & Wellington, C. L. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.23
Self-citationInvestigating the function of CLU in Alzheimer's Disease in in vitro and in vivo models
Vithal, T. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17014223.v1
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Dorey, E. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-6258
Carter, A. B. (2017) · D-Scholarship@Pitt (University of Pittsburgh)
AXL receptor tyrosine kinase regulates Apolipoprotein E expression
Zhao, W. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0372324
Title: Biochemical linkage of type 2 diabetes mellitus and Alzheimer’s disease
mahmoud, S., Abo–Elmatty, D. M., Mesbah, N. M., Mehanna, E. T., & Hafez, M. M. (2019) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2019.12031.1031
PPARγ Agonists for the Treatment of Alzheimer's Disease
Jiang, Q., Mandrekar, S., & Landreth, G. E. (2007) · Springer eBooks · doi:10.1007/7355_2007_014
Identification of Genes with Altered Roles in Transcription Network in Alzheimer's Disease
Hua, J., & Yu, S. P. (2021) · International Conference on Bioinformatics and Biomedical Technology (ICBBT) · doi:10.1145/3473258.3473273
Faculty Opinions recommendation of Neuroinflammation in Alzheimer's disease.
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725413893.793537457
Yadav, R., Mani, R. J., Kumar, A. H. S., Ahmad, S., & Katare, D. P. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2990 · Cited by 1
APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease
Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_66-1
Hanbouch, L. (2017) · theses.fr (ABES) · doi:10.70675/c4d2c894zf69dz4ae4z9ab1zf4135d0efa12
Castelot, R. (2024) · theses.fr (ABES) · doi:10.70675/c2a7ce1ez8caaz4593zbb3azae8add8055b5
APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease
Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_66
Cholesterol 24S-hydroxylase: Involvement in brain injury and disease
Cartagena, C. M. (2008) · DigitalGeorgetown (Georgetown University Library)
Saul, A. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3915
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
Metadata
- Authors
- Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., Poirier, J., Van Nostrand, W., & Wellington, C. L.
- Affiliations
- University of British Columbia (CA)
- McGill University Research Centre for Studies in Aging (CA)
- Corresponding author
- Wellington, Cheryl L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 280
- Issue
- 52
- Pages
- 43243-43256
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2151049459
- Cited by
- 233
- References
- 95
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 5 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 10 · 2015: 10 · 2014: 20 · 2013: 13 · 2012: 19
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Heart and Stroke Foundation of Canada
- Child and Family Research Institute
- Alzheimer Society
- National Institutes of Health
- Canadian Institutes of Health Research
- National Institute of Neurological Disorders and Stroke (R01NS036645, NS36645)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- ABCA1, apolipoprotein E, amyloid deposition, Alzheimer's disease, amyloid-beta, amyloid precursor protein, presenilin 1, APP/PS1 mice, cholesterol transport, amyloidogenesis
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Apolipoproteins E, Brain, Cerebral Cortex, Cholesterol, Densitometry, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Hippocampus, Humans, Immunohistochemistry, Lipids, Membrane Proteins, Mice, Inbred C57BL, Blotting, Western, ATP-Binding Cassette Transporters, Transgenes, Guanidine, Mice, Presenilin-1, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
